Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind, Randomised, Placebo Controlled Clinical Trial

This study has been completed.
Sponsor:
Collaborator:
Eisai Co., Ltd.
Information provided by:
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00327730
First received: May 17, 2006
Last updated: September 5, 2008
Last verified: September 2008
  Purpose

The purpose of this study is to evaluate the efficacy of Eperisone HCl in the treatment of Acute Musculoskeletal spasm associated with Low-Back Pain.


Condition Intervention Phase
Muscle Spasm; Back Pain
Drug: Eperisone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • The present study will be conducted with an objective of comparing the efficacy of Eperisone-HCl (Myonal) versus placebo in the treatment of acute musculoskeletal spasm associated with low back pain.

Secondary Outcome Measures:
  • The present study will be conducted with a secondary objective of comparing the tolerability of Eperisone-HCl (Myonal) versus placebo.

Enrollment: 240
Study Start Date: October 2006
Detailed Description:

This is a multi-center trial, which will be conducted in a total of 240 patients (120 patients in each treatment group). Patients attending the out-patient setting of traumatology and orthopedic departments of the study centers will be screened for lumbar pain and spasm by clinical and radiological examination for inclusion. In this study, it has been planned to enroll a total of 240 patients with 120 patients in each group. The total duration of treatment will be 14 days. Patients will be screened for baseline parameters and will then be randomized, as per the predetermined randomization schedule, into two groups. Patients will be treated with either Eperisone-HCl (Myonal) or placebo for a period of 14 days. After the baseline-screening visit (Day 1), the patients would be asked to follow up on day 3, day 7, and day 14. During each visit, a complete general examination and clinical evaluation of efficacy parameters would be done. Adverse events would be monitored during the study period and would be recorded in the Case Report Form (CRF). At the end of the treatment, Global Assessment of Response to Therapy by Physicians and Patients (PGART) would be done for efficacy and tolerability separately.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients of either sex between 18 to 60 years of age.
  2. Patients with confirmed diagnosis of Acute Musculoskeletal spasm with Low Back Pain due to:

    • Spondylosis deformans
    • Prolapsed Intervertebral Disc (PID)
    • Muscle sprains with spasms
  3. Patients who are willing to take the medications as directed and willing to come for follow-ups.
  4. Patients who are willing to comply with the protocol requirements.
  5. Patients who are willing to give the written informed consent.

Exclusion Criteria:

  1. Patients with other associated spasm conditions like:

    • Muscle sprains with spasms of hip/knee/ankle
    • Traumatic pain with spasms
    • Cervical Spondylitis
    • Pain & spasm associated with fractured bone.
  2. Patients who had taken any form of skeletal muscle relaxant in the previous 7 days.
  3. Patients with hypersensitivity to any of the ingredients of the test & control formulations.
  4. Pregnant/Lactating women or women of child bearing potential not following adequate contraceptive measures.
  5. Patients unwilling or unable to comply with the study procedures.
  6. Patients having a history of severe acute infection, major surgery or trauma, severe metabolic, endocrine or electrolyte disturbances and seizures in preceding 8 weeks.
  7. Patients having severe renal insufficiency defined by a creatinine value above 2.5 mg/dl.
  8. Patients having severe hepatic insufficiency defined by an SGOT or SGPT value equal or higher than the threefold normal values of the respective laboratory reference value.
  9. Patients having any of the following disorders:

    • Renal failure
    • Bulimia
    • Hypo and Hyperthyroidism
    • Nephrotic syndrome
    • Anorexia nervosa
    • Biliary obstruction
    • Severe cardiac dysfunction.
  10. Patients having uncontrolled diabetes mellitus, or any other metabolic or endocrine disorder.
  11. Patients that have received treatment with any investigational drug in the preceding 4 weeks.
  12. Patients likely to be non-compliant (alcohol, smoking or drug abusers).
  13. Any condition that, in the opinion of the investigator, does not justify patient's inclusion in the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00327730

Locations
India
M.R. Medical College
Gulbarga, Karnataka, India, 585 104
Grant Medical College Sir J.J. Group of Hospitals
Byculla, Mumbai, Maharashtra, India, 400 008
L.T. M. Medical College and General Hospital
Sion, Mumbai, Maharashtra, India, 400 022
Post Graduate Institute of Medical Education and Research (PGI)
Chandigarh, Punjab, India, 160 012
Sponsors and Collaborators
Eisai Inc.
Eisai Co., Ltd.
Investigators
Study Director: Dr. Dilip Pawar Eisai Pharmaceuticals India Pvt. Ltd
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00327730     History of Changes
Other Study ID Numbers: E0646-AS91-301
Study First Received: May 17, 2006
Last Updated: September 5, 2008
Health Authority: India: Ministry of Health

Keywords provided by Eisai Inc.:
Muscle
Spasm
Back
Pain

Additional relevant MeSH terms:
Back Pain
Low Back Pain
Spasm
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neuromuscular Manifestations
Eperisone
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Muscle Relaxants, Central
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Parasympatholytics
Autonomic Agents
Vasodilator Agents
Anticonvulsants

ClinicalTrials.gov processed this record on April 17, 2014